Macroglobulinemia: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 28: | Line 28: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
Revision as of 12:59, 18 March 2025
Macroglobulinemia is a type of blood cancer that originates from B cells, a type of white blood cell. It is characterized by the overproduction of immunoglobulin M (IgM), a type of antibody, which leads to increased blood viscosity, or thickness. This condition is also known as Waldenström's macroglobulinemia, named after the Swedish physician Jan Gosta Waldenström who first described the disease in 1944.
Symptoms
The symptoms of macroglobulinemia can vary widely, but often include fatigue, weakness, and weight loss. Other symptoms may include bleeding, bruising, swelling, and problems with vision or hearing. In severe cases, the disease can lead to organ failure.
Causes
The exact cause of macroglobulinemia is unknown, but it is thought to be related to genetic mutations in the B cells. These mutations cause the cells to grow and divide uncontrollably, leading to the overproduction of IgM.
Diagnosis
Diagnosis of macroglobulinemia is typically made through blood tests, which can detect the presence of excess IgM. Other tests, such as bone marrow biopsy, may also be used to confirm the diagnosis.
Treatment
Treatment for macroglobulinemia typically involves chemotherapy, immunotherapy, or a combination of both. In some cases, stem cell transplantation may be considered.
Prognosis
The prognosis for macroglobulinemia varies widely, depending on the stage of the disease and the patient's overall health. However, with appropriate treatment, many patients can live for many years with the disease.


